Abstract 1003P
Background
Multimodal approach, a combination of various treatment modalities, has emerged as a potential approach for treating uHCC. It is utilized to help relieve tumor burden, slow progression, and provide survival benefits to patients. However, controversies remain in using a multimodal approach in the management of uHCC, and is still debatable. This study aims to evaluate the efficacy and safety of triple combination therapy composed of Transarterial chemoembolization (TACE), TKI, and ICI compared to dual combination therapy (TACE+TKI, TKI+ICI).
Methods
Eligible studies published before March 30, 2023 were retrieved. Outcomes of interest included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and occurrence of adverse events (AEs). Literature search was done using through PubMed, Embase, and Cochrane Library. Risk of bias assessment was done using ROBINS-I tool.
Results
Thirteen retrospective studies were included representing 1005 patients with uHCC. There was low to moderate bias among the studies. Triple combination therapy was associated with a significant improvement in survival compared to dual combination therapy: median OS, pooled HR 0.46 (95% CI: 0.39-0.54, p<0.00001) and median PFS, pooled HR 0.41 (95% CI: 0.28-0.61, p<0.00001). Triple combination therapy was also associated with a significant increase in tumor response compared to dual combination therapy: ORR, pooled RR 1.76 (95% CI: 1.51-2.06, p<0.00001), and DCR, pooled RR 1.36 (95% CI 1.24-1.49, p-<0.00001). However, triple combination therapy had a higher risk of adverse events compared to dual combination therapy, pooled RR 1.49 (95% CI: 1.19, 1.86, p=0.0004). There was no significant heterogeneity found among the studies included.
Conclusions
Triple combination therapy was associated with significantly better outcomes but higher risk of adverse events than dual combination therapy in patients with uHCC so careful consideration of the risks and benefits must be done before initiating treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18